
    
      Selected patients of female gender, above 50 y.o, and after a biopsy of Luminal-like Breast
      Cancer will go under aromatase inhibitor, from the diagnosis day till the surgical therapy to
      be decided (if so).In this study are going to be included patients that refuse surgical
      treatment, remaining this way in an "active surveillance". This last group is going to be
      randomised in order to recieve hormontherapy plus placebo vs hormontherapy plus
      acetolisalicilic acid.

      In this way, authors want to investigate if:

        1. st This approach influences the tumor biology

        2. nd This approach influences tumor pathologic response and progression free survival.

        3. rd It is a valid approach and in which grade, for patients that refuse surgical
           treatment
    
  